Author:
Silva-Fernandez Lucia,Hyrich Kimme
Publisher
Springer Science and Business Media LLC
Reference10 articles.
1. Soliman, M. M. et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. (Hoboken) 64, 1108–1115 (2012).
2. Gomez-Reino J. J. et al. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann. Rheum. Dis. 71, 382–385 (2012).
3. Chatzidionysiou, K. & van Vollenhoven, R. F. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. Scand. J. Rheumatol. 42, 190–195 (2013).
4. Chatzidionysiou, K. et al. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann. Rheum. Dis.
http://dx.doi.org/10.1136/annrheumdis-2013-204714
.
5. Emery, P. et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann. Rheum. Dis.
http://dx.doi.org/10.1136/annrheumdis-2013-203993
.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献